Daewoong's drug targets ₩100 bil market as 2nd P-CAB

By Kim, Jin-Gu | translator Alice Kang

21.12.30 12:09:38

가나다라 0

Concluding co-promotion for Nexium, Daewoong Pharmaceutical plans to ‘all-in’ on fexuprazan.

HK inno.N extends K-CAB indication, adds formulation to establish additional defense against newly introduced drugs

Daewoong Pharmaceutical succeeded in receiving approval for its potassium-competitive acid blocker (P-CAB) ‘Fexclu (fexuprazan)’ for the treatment of gastroesophageal reflux disease (GERD).

It is being predicted that the new drug introduced will unfold a full-fledged competition with HK inno.N’s ‘K-CAB (tegoprazan), a GERD treatment that grew to record ₩100 billion in annual prescriptions in only 3 years since its release.

◆Received marketing authorization 14 years after starting development … 34th homegrown new drug

The Ministry of Food and Drug Safety granted marketing authorization of Daewoong’s Fexclu tablet on the 30th. Fexclu will likely be design

Kim, Jin-Gu(kjg@dailypharm.com)

If you want to see the full article, please JOIN US (click)